Overview

Defibrotide Dose-escalation for SOS Post-HSCT

Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
0
Participant gender:
All
Summary
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
New York Medical College
Treatments:
Defibrotide
Criteria
Inclusion Criteria:

- HCT recipients (Auto or Allograft)

- SOS/VOD as defined by Cairo/Cooke Diagnostic criteria (1) (Table 3) with either renal
and/or pulmonary dysfunction as defined by Cairo/Cooke Grading criteria (1) (Appendix
I).

- Unresponsive to standard defibrotide therapy as defined by at least one of the
following:

- Patients with SOS/VOD failing to obtain a complete response (CR) defined by Grade I or
less by Cairo/Cooke Grading criteria (1) (Appendix I). This would therefore include
patients with stable disease after at least 14 days of defibrotide or partial response
after at least 21 days of defibrotide (25mg/kg/day).

- Progressive disease defined by progression of at least one grade or more from
diagnostic grade as defined by Cairo/Cooke Grading criteria (1) (Appendix I) following
at least 7 days of defibrotide (25mg/kg/day).

- Age 1 month - 75 years

Exclusion Criteria:

- Patients who did not receive HCT.

- Concomitant systemic anticoagulation (excluding central venous line management,
fibrinolytic instillation for central venous line occlusion, management of
intermittent dialysis or ultrafiltration of CVVH).

- Active bleeding and/or hemorrhage of at least grade 2 and above.

- History of development of Grade III/IV anaphylaxis probably or directly secondary to
defibrotide.

- Female patients who are pregnant or breast feeding.